Lexon’s Oblio Named as One of TIME’s 100 Best Inventions Of 2020
26.11.2020 10:57:00 EET | Business Wire | Press release
20 years after making the cover of TIME with their flagship Tykho radio, French design brand Lexon is back on the prestigious publication to reiterate its mission to continuously create disruptive, useful and affordable design objects that improve our daily lives.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201125005899/en/
Oblio (Photo: Business Wire)
More than just highlighting the groundbreaking French invention, TIME award confirms Oblio’s position as a must-have innovation for today’s world, as it has been crafted in-house primarily as a sleek UV-C sanitizer to prevent the spread of harmful viruses and bacteria that are found on our smartphones, using its built-in UV-C LED technology located on its front interior. UV-C LEDs destroy and eradicate the DNA of microorganisms found in viruses, bacteria, mold, and germs.
Capable of fully sanitizing a single surface at a time, Oblio can deliver a 360° disinfection by simply flipping the phone to expose its second surface for a 20-minute cycle. In terms of effectiveness, Oblio has been proven through lab testing to kill 99.9% of viruses, including H1N1.
“Since the beginning of the pandemic, we have seen a growing interest for this product category (UV sanitizer) and therefore, the market becoming rapidly populated with lots of unaesthetic neither truly legitimate solutions. In this context, we're extremely honored and proud to be recognized and awarded for our product's distinct design, its effectiveness and reliability to sanitize our daily essentials and the opportunity to become a must-have solution for today's home and offices.
With the help of media like TIME who are raising awareness around Oblio, with the support and trust of our retail partners who are listing it, we are together making UV-C technology becoming more popular and accessible to everyone, allowing us to collectively participate in a positive change, leveraging innovation to adapt to new behaviors and prevent the spread of virus, which is our common responsibility.” Says Boris Brault, Lexon CEO.
Also acting as a 10W wireless charger, Oblio can fully charge a smartphone in 3 hours and comes with an LED indicator that confirms the correct positioning and charging status of the mobile device.
Appropriately, 'Oblio' is rooted in the Italian meaning for “forgot” the native language of designers’ Manuela Simonelli & Andrea Quaglio. The name hints to the product’s vase shape, thoughtfully crafted to help people disconnect from their screens and enjoy the freedom to be more present for each other, while discreetly sanitizing any mobile phone and fast-charging all Qi-enabled smartphones such as the latest iPhone and Android.
“With such achievements, we’re also proving that France remains an indisputable territory where creativity, innovation and design are prerequisite to sustainable growth, and we hope we can inspire entrepreneurs to believe in their projects and bring them to life.” adds Brault.
Today, Oblio is already available at the most prominent retailers worldwide such as Best Buy, Nordstrom, MoMA Design Store in the US, Fnac Darty in Europe and many more, as well as the official online store: lexon-design.com.
- MSRP of 79,90€/$.
- Available in 4 colors.
- Compatible with all mobile phone for sanitizing function, and all Qi-enabled smartphones such as the latest iPhone & Android devices for the wireless charging function.
- Download the product sheet
- Download the product photos
- Download the lifestyle photos
About Lexon:
Since its creation in 1991, Lexon has relentlessly pushed the limits and created a difference in the world of design while remaining true to its commitment to make small objects useful, beautiful, innovative and affordable. Whether in electronics, audio, travel accessories, office or leisure, Lexon has established a special relationship with creativity and partnered with the best designers around the world to create timeless collections of lifestyle products. Following its recent acquisition by BOW Group, a global player in the lifestyle and wearable consumer markets, Lexon is writing a new chapter in its history, experiencing a staggering international growth and digital expansion. Today, with nearly 30 years of existence, more than 200 awards, collaboration with some of the most renowned designers, a retail presence in more than 90 countries across the Globe, Lexon has truly established itself as a worldly-known French design brand.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201125005899/en/
Contact information
International Media contact:
Annabel Corlay a.corlay@lexon-design.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
